SurModics
SRDX
#6822
Rank
$0.61 B
Marketcap
$42.98
Share price
0.00%
Change (1 day)
7.69%
Change (1 year)
Categories

P/E ratio for SurModics (SRDX)

P/E ratio as of December 2025 (TTM): -34.9

According to SurModics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -34.9431. At the end of 2024 the company had a P/E ratio of -39.2.

P/E ratio history for SurModics from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-39.2-142.07%
202393.2-733.75%
2022-14.7-103.97%
2021370-57.45%
2020870908.43%
201986.3-120.09%
2018-430
201634.863.07%
201521.3-15.04%
201425.15.03%
201323.9-23%
201231.1

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Nektar Therapeutics
NKTR
-13.6-60.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
33.2-194.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Enzo Biochem
ENZB
-3.33-90.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Alkermes
ALKS
14.2-140.51%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Johnson & Johnson
JNJ
19.4-155.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
15.6-144.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Agilent Technologies
A
34.7-199.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Heron Therapeutics
HRTX
-16.4-53.14%๐Ÿ‡บ๐Ÿ‡ธ USA
PerkinElmer
PKI
15.0-142.83%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.